Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: hometown35 who wrote (68996)	1/29/2000 4:36:00 PM
From: 2MAR$	Read Replies (1) \| Respond to of 108040

VLTS ...in the medical/biotech arena , been on a nice up-trend since trading at a low of 5 last may to a close 13 7/8 (+1 9/16) on friday with triple the average volume @ 1mil shrs traded... VLTS has seemed to have made a significant announcement at the last Hambrecht & Quist Healthcare Conference in San Francisco, Jan 10th 2000, that it is extending its product line by developing gene delivery systems for secreted proteins: biz.yahoo.com Seems it has attracted some eyes at various bio conferences,and has several phases I & II clinical trials involving Interferon Gene therapy... earnings due out on feb 8th, hit new high on jan 7 of $13 1/4.... Valentis is working with F. Hoffman–La Roche ("Roche") to develop gene-based immunotherapeutics for cancer based on the interleukin-2 ("IL-2"), interleukin-12 ("IL-12") and interferon alpha ("IFN-a ") genes. Phase IIa clinical trials in the U.S. and Germany have been completed for the first gene medicine from this collaboration which incorporates the human IL-2 gene formulated with a cationic lipid formulation for the treatment of head and neck cancer. The Phase IIa trial of the IL-2 gene medicine showed that the product was safe and well tolerated, with evidence of IL-2 expression up to 11 days post-treatment. A Phase IIb with IL-2 began in June 1999. megabios.com. Located in Burlingame, Ca , VLTS has an exclusive license to certain patents and patent applications held by The Regents of the University of California related to in vivo, non-viral delivery of genes using positively charged lipids, including delivery by various modes of administration and for use in the treatment of cystic fibrosis. Has the following Academic collaborations: megabios.com. IsValentis has products in human clinical trials, either via physician-sponsored INDs, on our own or with our partners working on several clinical trials in phase 1 & II for head and neck cancer in conjunction with Roche with phase IIb begun for this product in june 99. A Phase IIa study for malignant melanoma using a combination of IL-2 and a superantigen (SEB) gene is being conducted under a physician-sponsored IND which began in May 1998. . The trial is being conducted by Dr. Pat Walsh at the University of Colorado Health Sciences Center. The costs of the trial are being supported in part by a clinical grant from the National Cancer Institute. In 2000, Valentis is planning to put three additional products into clinical testing. megabios.com. nice to see you posting hometown<i/>, always feel free! VLTS thread Subject 27855 :-) 2MAR$ :

To: hometown35 who wrote (68996)	1/29/2000 8:29:00 PM
From: hometown35	Read Replies (1) \| Respond to of 108040

Just found this on Linux Home site: Sat, 29 Jan 2000 02:43:48pm "Corel channeled its considerable application expertise into a Linux release that marks a turning point for the OS industry. Corel Linux OS Deluxe is the first Linux -- in fact, the first Unix of any kind -- that can realistically take the place of a Windows or Macintosh desktop. It has a few warts, but Corel's Linux debut is a stunner." "For employees who do most of their work in office-productivity applications and on the Web, Corel Linux is an excellent platform to deploy. The support costs for the Corel Linux OS promise to be lower than for Windows, with an automated system-update utility and an interface that makes the transition from Windows or the MacOS painless." "Also, Corel Linux OS is significantly more affordable than a copy of Windows 2000 Professional upgrade ($219), plus Office 2000 Professional upgrade ($349). You'll pay $568 for that combo, compared to $89.95 for Corel Linux OS Deluxe. With its Windows ease of use and Linux power, Corel Linux OS Deluxe makes sense both technically and financially."